Nalaganje...
Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. Median survival for metastatic patients is six to nine months and survivors beyond one year are exceptional. Pancreatic cancer is resistant to conventional chemotherapy and is often diagnosed at advanced stages. However, immuno...
Shranjeno v:
| izdano v: | Cureus |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Cureus
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4731256/ https://ncbi.nlm.nih.gov/pubmed/26870619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.435 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|